Aavhanzr Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.80 M
- Paid Up Capital ₹ 3.80 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.95 M
- Satisfied Charges ₹ 1.25 Cr
- Revenue Growth -10.90%
- Profit Growth -112.41%
- Ebitda -46.57%
- Net Worth -0.87%
- Total Assets -11.54%
About Aavhanzr Pharmaceuticals
Aavhanzr Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 March 2016 (Eight years and 11 months 2 days old ). Its registered office is in Bangalore, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.80 M and a paid-up capital of Rs 3.80 M.
The company currently has active open charges totaling ₹5.95 M. The company has closed loans amounting to ₹1.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vijay Jain and Hansraj Munot serve as directors at the Company.
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51109KA2016PTC087251
- Company No.
087251
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Aavhanzr Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Jain  | Director | 11-Dec-2017 | Current |
| Hansraj Munot | Director | 24-Mar-2016 | Current |
Financial Performance of Aavhanzr Pharmaceuticals.
Aavhanzr Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.9% decrease. The company also saw a substantial fall in profitability, with a 112.41% decrease in profit. The company's net worth dipped by a decrease of 0.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aavhanzr Pharmaceuticals?
In 2023, Aavhanzr Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.95 M
₹12.50 M
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Nov 2020 | Axis Bank Limited | ₹5.95 M | Open |
| 02 May 2018 | Others | ₹1.25 Cr | Satisfied |
How Many Employees Work at Aavhanzr Pharmaceuticals?
Unlock and access historical data on people associated with Aavhanzr Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aavhanzr Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aavhanzr Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
